drugset / Trial / NCT00972673

A Study of GW685698X in Healthy Japanese Male Subjects

NCT00972673

Phase 1 Completed 48 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.

Timeline

Start
2008-09-24
Primary completion
2008-12-19
Completion
2008-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 200 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 400 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 800 ug Inhaled

Indications